In a report released yesterday, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Altimmune (ALT), with a price target of $31.00. The company’s shares closed last Monday at $12.60.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 20.2% and a 50.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Altimmune with a $49.00 average price target.
See today’s analyst top recommended stocks >>
Based on Altimmune’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $721.6K and GAAP net loss of $16.77 million. In comparison, last year the company earned revenue of $1.63 million and had a GAAP net loss of $3.39 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
